1217816-76-6

1217816-76-6 structure

Name: RPR121056-d3
Chemical Name: RPR121056-d3
CAS Number: 1217816-76-6
Molecular Formula: C₃₃H₃₅D₃N₄O₈
Molecular Weight: 621.70
Catalog: Signaling Pathways Cell Cycle/DNA Damage Topoisomerase
Create Date: 2022-01-08 17:46:20
Modify Date: 2025-08-27 10:26:46
RPR121056-d3 is the deuterium labeled RPR121056. RPR121056 is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE[1][2].

Name	RPR121056-d3

Description	RPR121056-d3 is the deuterium labeled RPR121056. RPR121056 is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase Signaling Pathways >> Neuronal Signaling >> AChE
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Alvau MD, et al. Enzyme-Based Electrochemical Biosensor for Therapeutic Drug Monitoring of Anticancer Drug Irinotecan. Anal Chem. 2018 May 15;90(10):6012-6019.

Molecular Formula	C₃₃H₃₅D₃N₄O₈
Molecular Weight	621.70